Freshfields, Wachtell Drive $39B AstraZeneca-Alexion Deal
AstraZeneca, advised by Freshfields, will buy Wachtell-guided Alexion for roughly $39 billion, the companies said Saturday, in a deal that represents the largest acquisition of a U.S. target this year and...To view the full article, register now.
Already a subscriber? Click here to view full article